Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,349
datasets available to search
ShareScore release 0.9.0
Dataset results
2,349 results for “Gastric cancer”
Parthenolide induces ROS-dependent cell death in human gastric cancer cells
<p>Excel 1 - The original data-Parthenolide induces ROS-dependent cell death in human gastric cancer cellanalysis.</p><p>Supplemental Table 1 - Post-hoc Dunn's test for the effect of PN on the cell viability of MGC-803 cell.</p><p>Supplemental Table 2 - Post-hoc Dunn's test for the effect of PN on the cell colonies of MGC-803 cells.</p><p>Supplemental Table 3 - Post-hoc Dunn's test for the effect of PN and catalase on ROS Generation of MGC-803 cells</p><p>Supplemental Table 4 - Post-hoc Dunn's test for the effect of PN and catalase on cell viability of MGC-803 cells</p><p>Excel 2 - gene_sample_count from MGC-803 cells treated with DMSO compared with counterparts treated with PN </p>
Serum PM20D1 levels is associated with nutritional status and inflammatory factors in gastric cancer patients undergoing early enteral nutrition
<p>The statistical database.</p>
Anticancer bioactive peptide combined with oxaliplatin against gastric cancer by regulation of PI3K/AKT signaling via inhibition of TPX2
Open the record for dataset details and reuse information.
GBAP1 polymorphisms (rs140081212, rs1057941 and rs2990220) contribute to the reduced risk of gastric cancer
<p><strong><em>Propose:</em></strong> The purpose of this study is to evaluate the contribution of <em>GBAP1</em> genetic variants to the risk of gastric cancer (GC) occurrence among a Chinese Han population.</p> <p><strong><em>Methods:</em></strong> This study included 509 GC patients and 507 healthy controls. The genotypes of <em>GBAP1</em> polymorphisms were detected by Agena MassARRAY platform. Logistic regression analysis was used for the association between <em>GBAP1</em> polymorphisms and GC predisposition by calculating Odds ratio (OR) and 95% confidence interval (CI) adjusted for age and gender.</p> <p><strong><em>Results: </em></strong><em>GBAP1</em> rs140081212 (OR = 0.51, <em>p</em> = 4.50´10<sup>-07</sup>), rs1057941 (OR = 0.48, <em>p</em> = 1.19´10<sup>-08</sup>) and rs2990220 (OR = 0.46, <em>p</em> = 7.34´10<sup>-09</sup>) contribute to the reduced risk of GC incidence. Interestingly, the contribution of <em>GBAP1</em> genetic variants to GC susceptibility was associated with age, gender, BMI and the status of smoking and drinking. Besides, rs140081212 (OR = 0.47, <em>p</em> = 1.70´10<sup>-06</sup>), rs1057941 (OR = 0.43, <em>p</em> = 4.43´10<sup>-08</sup>) and rs2990220 (OR = 0.43, <em>p</em> = 2.66´10<sup>-07</sup>) variants had the relationship to the decreasing risk of gastric adenocarcinoma.</p> <p><strong><em>Conclusion: </em></strong>Our research suggested that <em>GBAP1</em> polymorphisms (rs140081212, rs1057941 and rs2990220) might provide a protective effect on GC occurrence among a Chinese Han population. Our finding might increase the understanding of molecular genetics in gastric carcinogenesis.</p> <p> </p>
Fig. 5 in Cytotoxicity of methanolic extract of Swertia petiolata against gastric cancer cell line SNU-5 is via induction of apoptosis ⁎
Fig. 5. Mitochondrial membrane potential (MMP %) of SNU-5 cells treated with indicated concentration of methanolic extract of plant for 48 h. The S. petiolata methanolic extracttreated SNU5 cells showed induction of MMP loss in a dose dependent manner.
Fig. 2. SNU5 in Cytotoxicity of methanolic extract of Swertia petiolata against gastric cancer cell line SNU-5 is via induction of apoptosis ⁎
Fig. 2. SNU5 cells were treated with indicated concentrations of methanolic extract of S. petiolata for 48 h and cells were prolonged for clonogenic assay for 21 days. The extract-treated SNU5 cells showed decrease in the percentage of colony formation as compared to control in a dose-dependent manner.
Fig. 1. SNU5 in Cytotoxicity of methanolic extract of Swertia petiolata against gastric cancer cell line SNU-5 is via induction of apoptosis ⁎
Fig. 1. SNU5 cells were treated with indicated concentration of methanolic extract of S. petiolata for 48 h. The extract-treated SNU5 cells showed nuclear condensation and marked fragmented in a dose dependent manner.
Fig. 3 in Cytotoxicity of methanolic extract of Swertia petiolata against gastric cancer cell line SNU-5 is via induction of apoptosis ⁎
Fig. 3. Cells were treated with different concentrations (a) control (b) 50 (c) 100 and (d) 150 μg/ml of extract for 48 h wherein apoptosis enhanced in a dose dependent manner as shown by flow cytometer using Annexin V/PI.
Fig. 4 in Cytotoxicity of methanolic extract of Swertia petiolata against gastric cancer cell line SNU-5 is via induction of apoptosis ⁎
Fig. 4. Production of ROS (%) SNU-5 cells treated with indicated concentration of methanolic extract of plant for 48 h. The S. petiolata methanolic extract-treated SNU5 cells showed the production of reactive oxygen species generated in a dose dependent manner.
Fig. 7 in Cytotoxicity of methanolic extract of Swertia petiolata against gastric cancer cell line SNU-5 is via induction of apoptosis ⁎
Fig. 7. Structures of the compounds tentatively identified from the methanolic extract of S. petiolata, (i) Chlorogenic acid (ii) p-Coumaric acid (iii) Ursolic acid (iv) Myrecetin 3-O- rahamnoside (v) Quercetin 3-arabinoside (vi) Kaempherol 3-O-glucoside (vii) Naringenin (viii) Genistein (ix) Isorhamnetin (x) Swerchirin.
Data from: Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study)
Objective: Few data regarding the incidence of cancer-associated thromboembolism (TE) are available for Asian populations. We investigated the incidence of TE (TEi) and its risk factors among gastric and colorectal cancer (GCC) patients who received chemotherapy in a daily practice setting. Design: A retrospective cohort study. Setting: A single institutional study that used data from Sapporo City General Hospital, Japan, on patients treated between January 2008 and May 2015. Participants: Five hundred Japanese GCC patients who started chemotherapy from January 2008 to May 2015. Primary and secondary outcome measures: TE was diagnosed by reviewing all the reports of contrast-enhanced computed tomography (CT) performed during the follow-up period. All types of thrombosis detected by CT or additional imaging tests, such as venous TE, arterial TE, and cerebral infarction, were defined as TE. Medical records of all identified patients were reviewed and potential risk factors for TE including clinicopathological backgrounds were collected. We defined the following patients as 'active cancer'; patients with unresectable advanced GCC, cancer recurrence during or after completing adjuvant (Adj) chemotherapy, and/or presence of other malignant tumours. Results: Of the 500 patients, 70 patients (14.0%) developed TE during the follow-up period. TEi was 9.2% and 17.3% in gastric and colorectal cancer patients, 18.1% and 3.5% in active and non-active cancer patients, and 24.0% and 12.9% in multiple and single primary, respectively. Multivariate logistic regression analysis showed that colorectal cancer (odds ratio [OR], 2.371; 95% confidence interval [CI], 1.328 to 4.233), active cancer (OR 7.593; 95% CI 2.950 to 19.543), and multiple primary (OR 2.527; 95% CI 1.189 to 5.370) were independently associated with TEi. Conclusion: TEi was 14.0% among Japanese GCC patients received chemotherapy, and was significantly higher among patients with colorectal cancer, active cancer, and multiple primary than among those with gastric cancer, non-active cancer, and single primary, respectively.
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
ClinicalTrials.gov study NCT04675866. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer
ClinicalTrials.gov study NCT02085031. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Gastric Cancer Sentinel Lymph Node Mapping
ClinicalTrials.gov study NCT03049345. IPD Sharing: NO. Countries: 1. Publications: 3.
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
ClinicalTrials.gov study NCT03192735. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
ClinicalTrials.gov study NCT00144378. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
ClinicalTrials.gov study NCT03468712. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer
ClinicalTrials.gov study NCT06687291. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
ClinicalTrials.gov study NCT01396707. IPD Sharing: UNDECIDED. Countries: 1. Publications: 19.
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
ClinicalTrials.gov study NCT00152217. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.